

UNITED STATES JUDICIAL PANEL
on
MULTIDISTRICT LITIGATION

IN RE: VALSARTAN PRODUCTS LIABILITY
LITIGATION

MDL No. 2875

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO -1)

On February 14, 2019, the Panel transferred 5 civil action(s) to the United States District Court for the District of New Jersey for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. *See* F.Supp.3d (J.P.M.L. 2019). Since that time, no additional action(s) have been transferred to the District of New Jersey. With the consent of that court, all such actions have been assigned to the Honorable Robert B. Kugler.

It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the District of New Jersey and assigned to Judge Kugler.

Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the District of New Jersey for the reasons stated in the order of February 14, 2019, and, with the consent of that court, assigned to the Honorable Robert B. Kugler.

This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the District of New Jersey. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel.

Inasmuch as no objection is pending at this time, the stay is lifted.

Feb 25, 2019

CLERK'S OFFICE
UNITED STATES
JUDICIAL PANEL ON
MULTIDISTRICT LITIGATION

FOR THE PANEL:



Jeffery N. Lüthi
Clerk of the Panel

I HEREBY CERTIFY that the above and
foregoing is a true and correct copy
of the original on file in my office.
UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY
WILLIAM T. WALSH, CLERK
Clerk of the Panel

**IN RE: VALSARTAN PRODUCTS LIABILITY
LITIGATION**

MDL No. 2875

SCHEDULE CTO-1 – TAG-ALONG ACTIONS

DIST DIV. C.A.NO. CASE CAPTION

ALABAMA NORTHERN

ALN 5 19-00150 Sen v. Zhejiang Huahai Pharmaceutical Co LTD et al

ARKANSAS WESTERN

ARW 2 19-02017 Selph v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al

CALIFORNIA CENTRAL

CAC 8 19-00180 Daniel Winiecki v. Zhejiang Huahai Pharmaceutical Co., LTD. et al

CALIFORNIA EASTERN

CAE 1 19-00212 Avedikian v. Zhejiang Huahai Pharmaceutical Co., Ltd et al

CALIFORNIA NORTHERN

CAN 5 19-00253 Guiton v. Zhejiang Huahai Pharmaceutical Co., Ltd et al

FLORIDA MIDDLE

FLM 2 18-00710 Molinaro v. Prinston Pharmaceutical Inc. et al

FLORIDA NORTHERN

FLN 4 19-00023 BARBER v. ZHEJIANG HUAHAI PHARMACEUTICAL CO LTD et al

FLORIDA SOUTHERN

FLS 1 18-25260 MSP Recovery Claims, Series LLC v. Huahai US Inc. et al

GEORGIA NORTHERN

GAN 1 19-00475

Martey v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al

INDIANA SOUTHERN

INS 1 19-00279

BAKER v. MYLAN INC. et al

INS 4 19-00022

WILLIAMS v. ZHEJIANG HUAHAI PHARMACEUTICALS CO., LTD. et al

LOUISIANA EASTERN

LAE 2 19-00078

Slavich v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al

LAE 2 19-00322

Kleinman v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al

LOUISIANA WESTERN

LAW 6 18-01497

Gremillion v. Zhejiang Huahai Pharmaceutical Co Ltd et al

MASSACHUSETTS

MA 1 18-12339

Longwell v. Camber Pharmaceuticals, Inc. et al

MA 1 19-10074

Barboza et al v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al

MA 3 19-30014

Williams v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al

MINNESOTA

MN 0 19-00091

Tack et al v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al

NEW YORK EASTERN

NYE 2 18-06916

Cacaccio v. Mylan Pharmaceuticals, Inc. et al

NYE 2 19-00332

Nelson v. Teva Pharmaceutical Industries, Ltd. et al

OHIO NORTHERN

OHN 3 19-00233

Pollock v. Zhejiang Huahai Pharmaceutical Co., Ltd et al

PENNSYLVANIA WESTERN

PAW 2 19-00046

RODICH-ANNESE v. SOLO HEALTHCARE U.S., LLC et al

TENNESSEE EASTERN

TNE 3 19-00040

Holland et al v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al (JRG3)